Iron chelation therapy with deferasirox induced complete remission in a patient with chemotherapy-resistant acute monocytic leukemia

Anticancer Research

Volumn 31, Issue 5, 2011, Pages 1741-1744

  Fukushima, Toshihiro ^a   Kawabata, Hiroshi ^b   Nakamura, Takuji ^a   Iwao, Haruka ^a   Nakajima, Akio ^a   Miki, Miyuki ^a   Sakai, Tomoyuki ^a   Sawaki, Toshioki ^a   Fujita, Yoshimasa ^a   Tanaka, Masao ^a   Masaki, Yasufumi ^a   Hirose, Yuko ^a   Umehara, Hisanori ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Acute myelogenous leukemia; Chemotherapy resistant; Complete remission; Deferasirox; Iron chelation therapy; Iron overload

Indexed keywords

CREATININE; DEFERASIROX; FERRITIN; SULPERAZON;

ACUTE MONOCYTIC LEUKEMIA; AGED; ANEMIA; ARTICLE; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER REGRESSION; CASE REPORT; CHOLECYSTITIS; CREATININE BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; ERYTHROCYTE TRANSFUSION; FERRITIN BLOOD LEVEL; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IRON CHELATION; LEUKOPENIA; MALE; MYELOFIBROSIS; PRIORITY JOURNAL; SPECTRAL KARYOTYPING; THERAPY RESISTANCE;

AGED; AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BENZOIC ACIDS; CHELATION THERAPY; DRUG RESISTANCE, NEOPLASM; ERYTHROCYTE TRANSFUSION; HUMANS; IRON CHELATING AGENTS; LEUKEMIA, MYELOMONOCYTIC, ACUTE; MALE; REMISSION INDUCTION; SALVAGE THERAPY; TREATMENT OUTCOME; TRIAZOLES;

EID: 79958124637     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Kohgo Y, Ikuta K, Ohtake T, Torimoto Y and Kato J: Body iron metabolism and pathophysiology of iron overload. Int J Hematol 88: 7-15, 2008.
2. Dröge W: Free radicals in the physiological control of cell function. Physiol Rev 82: 47-95, 2002.
3. Malcovati L, Delia Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E, Passamonti F, Arcaini L, Maffioli M, Bernasconi P, Lazzarino M and Cazzola M: Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 23: 7594-7603, 2005. (Pubitemid 46291823)
4. Malcovati L, Germing U, Kuendgen A, Delia Porta MG, Pascutto C, Invernizzi R, Giagounidis A, Hildebrandt B, Bernasconi P, Knipp S, Strupp C, Lazzarino M, Aul C and Cazzola M: Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25: 3503-3510, 2007. (Pubitemid 47315575)
5. Bennett JM: Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol 83: 858-861, 2008.
6. Rose C, Brechignac S, Vassilief D, Pascal L, Stamatoullas A, Guerci A, Larbaa D, Dreyfus F, Beyne-Rauzy O, Chaury MP, Roy L, Cheze S, Morel P and Fenaux P: Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM. Leuk Res 34: 864-870, 2010.
7. Fox F, Kündgen A, Nachtkamp K, Strupp C, Haas R, Germing U and Gattermann N: Matched-pair analysis of 186 MDS patients receiving iron chelation therapy or transfusion therapy only. Blood 114: 694a, 2009.
8. Leitch HA, Leger CS, Goodman TA, Wong KK, Wong DHC, Ramadan KM, Rollins MD, Bamett MJ, Galbraith PF and Vickars LM: Improve survival in patients with myelodysplastic syndrome receiving iron chelation therapy. Clin Leuk 2: 205-211, 2008.
9. Jensen PD, Heickendorff L, Pedersen B, Bendix-Hansen K, Jensen FT, Christensen T, Boesen AM and Ellegaard J: The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol 94: 288-299, 1996. (Pubitemid 26247987)
10. Messa E, Cilloni D, Messa F, Arruga F, Roetto A and Saglio G: Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis. Acta Haematol 120: 70-74, 2008.
11. Di Tucci AA, Murru R, Alberti D, Rabault B, Deplano S and Angelucci E: Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670). Eur J Haematol 78: 540-542, 2007. (Pubitemid 46753589)
12. Hershko C, Link G and Cabantchik I: Pathophysiology of iron overload. Ann N Y Acad Sci 850: 191-201, 1998.
13. Ghoti H, Amer J, Winder A, Rachmilewitz E and Fibach E: Oxidative stress in red blood cells, platelets and polymorphonuclear leukocytes from patients with myelodysplastic syndrome. Eur J Haematol 79: 463-467, 2007. (Pubitemid 350126678)
14. Greenberg PL, Koller CA, Cabantchik ZI, Warsi G, Glynos T, Paley C and Schiffer C: Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes. Leuk Res 34: 1560-1565, 2010.
15. Ghoti H, Fibach E, Merkel D, Perez-Avraham G, Grisariu S and Rachmilewitz EA: Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndromes. Heamtologica 95: 1433-1434, 2010.
16. Shimohakamada Y, Shinohara K and Fukuda N: Remission of acute myeloblasts leukemia after severe pneumonia treated with high-dose methylprednisolone. Int J Hematol 74: 173-177, 2001. (Pubitemid 33760068)
17. Maywald O, Buchheidt D, Bergmann J, Schoch C, Ludwig WD, Reiter A, Hastka J, Lengfelder E and Hehlmann R: Spontaneous remission in adult acute myeloid leukemia in association with systemic bacterial infection- case report and review of the literature. Ann Hematol 83: 189-194, 2004. (Pubitemid 38292241)
18. Fozza C, Bellizzi S, Bonfigli S, Campus PM, Dore F and Longinotti M: Cytogenetic and hematological spontaneous remission in a case of acute myelogenous leukemia. Eur J Haematol 73: 219-222, 2004. (Pubitemid 39062247)
19. Ohyashiki JH, Kobayashi C, Hamamura R, Okabe S, Tauchi T and Ohyashiki K: The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1. Cancer Sci 100: 970-977, 2009.
20. Messa E, Carturan S, Maffè C, Pautasso M, Bracco E, Roetto A, Messa F, Arruga F, Defilippi I, Rosso V, Zanone C, Rotolo A, Greco E, Pellegrino RM, Alberti D, Saglio G and Cilloni D: Deferasirox is a powerful NF-κB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. Heamatologica 95: 1308-1316, 2010.
21. Braun T, Carvalho G, Coquelle A, Vozenin MC, Lepelley P, Hirsch F, Kiladjian JJ, Ribrag V, Fenaux P and Kroemer G: NF-κB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome. Blood 107: 1156-1165, 2006.
22. Chirnomas D, Smith AL, Braunstein J, Finkelstein Y, Pereira L, Bergmann AK, Grant FD, Paley C, Shannon M and Neufeld EJ: Deferasirox pharmacokinetics in patients with adequate versus inadequate response. Blood 114: 4009-4013, 2009.
23. Pullarkat V: Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye? Blood 114: 5251-5255, 2009.